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Determination of the enantiomeric composition is a relevant 
issue in different areas, including the synthesis of enantiopure 
chemicals and biologically active substances.[1] In pharmacology, 
the enantiomers exhibit different behavior in terms of activity, side-
effects, toxicity, metabolism or transport mechanism. Therefore, the 
development of analytical methods to assess the enantiomeric 
composition of chiral drugs is of great interest.[2] 
Direct determination of the enantiomeric excess (ee) can be 
achieved by polarimetry;[1] however, this technique presents some 
practical limitations, mainly related to sensitivity and low tolerance 
to impurities. Other commonly used analytical methods are based on 
GC and HPLC on chiral stationary phases; their main disadvantages 
are that they are time-consuming and require serial analysis, which 
limits the number of samples that can be studied.[3] Other methods 
have been developed in the last decades,[4] based on the 
determination of different properties; they include MS,[5] UV-Vis 
absorption spectroscopy,[6] IR thermography,[7] circular dichroism,[8] 
capillary electrophoresis,[9] NMR spectroscopy,[10] fluorescence 
spectroscopy,[11] biochemical assays,[12] etc. In spite of this effort, 
quantification of stereoisomer levels continues to be an important 
problem, and therefore further research is still required to develop 
new analytical methodologies. 
In principle, discrimination between enantiomers is possible 
making use of supramolecular host-guest interactions. In this 






analysis of the UV-Vis absorption or fluorescence spectra in the 
presence of cyclodextrins.[13] Proteins are another important class of 
chiral selectors. Particularly, serum albumins (SA) have been widely 
used as stationary phases for the chromatographic resolution of 
enantiomeric mixtures,[14] a concept based on the possible 
stereoselectivity of the binding process. 
Recently, we have explored the suitability of triplet excited 
states as reporters for the binding of drugs to transport proteins,[15] 
as the properties of these states are very sensitive to the experienced 
microenvironment.[16] Thus, laser flash photolysis (LFP) 
measurements have been performed on (S)- and (R)-flurbiprofen 
methyl esters (FBPMe) in the presence of human serum albumin 
(HSA). Actually, FBPMe is a prodrug of the nonsteroidal 
antiinflammatory drug flurbiprofen (FBP). In the absence of protein, 
after LFP at 266 nm (2.5 × 10-5 M, PBS, air), (S)-FBPMe exhibits a 
characteristic transient triplet-triplet absorption spectrum centered at 
360 nm,[17] with a lifetime (τT) of 1.5 µs. However, in the presence 
of 2.5 × 10-5 M HSA, two τT values are observed (31.5 and 4.1 
µs);[15a] they have been assigned to (S)-FBPMe inside the two well 
known HSA binding sites (named site I and site II by Sudlow).[18] 
From the relative contributions of the different τT values at various 
(S)-FBPMe/HSA ratios, it has been possible to determine the drug 
distribution among the bulk solution and the protein binding sites. 
The same trend, but with remarkably different triplet lifetimes 
(157.6 µs and 16.6 µs), has been observed for (R)-FBPMe/HSA 
systems.[15a] For both (S)- and (R)-FBPMe, the major (longer-lived) 
component under non-saturating conditions was assigned to FBPMe 
within site I, and the minor (shorter-lived) component corresponded 
to site II-bound FBPMe.  
With this background, we decided to make use of the chiral 
discrimination between the triplet lifetimes of (S)- and (R)- isomers 
in the supramolecular binding to SA for the development of a new 
methodology aimed at a rapid and reliable assessment of 
enantiomeric composition. The strategy is based on the 
determination of the percentage of both enantiomers from the 
relative contributions of the triplet lifetimes obtained from the decay 
curves in the presence of SA as chiral selector (Scheme 1). 
As HSA, most of the serum albumins have two high affinity  
binding sites for small organic compounds, although this is not 





[a] Dr. M. C. Jiménez, Prof. M. A. Miranda 
Departamento de Química- Instituto de Tecnología Química UPV-CSIC 
Universidad Politécnica de Valencia 
Camino de Vera s/n, Apdo 46022, Valencia, Spain 
Fax: (+)34963877344  
E-mail: mcjimene@qim.upv.es; mmiranda@qim.upv.es 
[b] Dr. I. Vayá, C. J. Bueno, Dr. M. C. Jiménez, Prof. M. A. Miranda 
Departamento de Química- Instituto de Tecnología Química UPV-CSIC 
Universidad Politécnica de Valencia 
Camino de Vera s/n, Apdo 46022, Valencia, Spain 
 Supporting information for this article is available on the WWW 











To prove the concept, a series of solutions containing (S)-and 
(R)-FBPMe (percentages from 0:100 to 100:0) in the presence of 
equimolar amounts of HSA were prepared and submitted to LFP. 












Figure 1. A. Decays (λ = 360 nm) for several (S)-FBPMe/(R)-FBPMe/HSA 
mixtures: 1/0/1 (black), 0.7/0.3/1 (red), 0.3/0.7/1 (blue) and 0/1/1 (green) after LFP at 
266 nm. B. LFP-determined against known real values, together with the linear fit of the 
experimental points. 
 
It can be clearly seen that, as expected, the decay trace lengthens 
with increasing amounts of (R)-FBPMe. To obtain accurate fittings, 
it was assumed that, in a given FBPMe/HSA mixture containing 
both FBPMe enantiomers, four different kinds of triplets are present: 
they are ascribed to (R)- and (S)- FBPMe, within site I and site II. 
Then, the multiexponential law for fitting the decay trace would be 





where τIS and τIIS are the triplet lifetimes of (S)-FBPMe in site I and 
site II of HSA, whereas τIR and τIIR are the corresponding values for 
the (R)-enantiomer. Assuming that the ratios AIS/AIIS and AIR/AIIR 
remain constant (70/30 and 68/32, respectively),[15a] the fitting of 
each decay trace allowed us to obtain AIS and AIR and hence the 
percentage of each FBPMe enantiomer. A plot of the LFP-
determined against known real values is given in Figure 1B and 
clearly validates the proposed methodology. 
 Similar results were obtained with porcine serum albumin 
(PSA), although in this case the key parameters were somewhat 
different (τIS = 41.2 µs, τIS = 6.0 µs, τIR = 95.3 µs, τIIR = 9.5 µs, 
AIS/AIIS = 53/47 and AIR/AIIR = 75/25). Selected decays and the 
linear plot of LFP-determined versus real enantiomeric composition 














Figure 2. A. Decays (λ = 360 nm) for several (S)-FBPMe/(R)-FBPMe/PSA mixtures: 
1/0/1 (black), 0.8/0.2/1 (red), 0.4/0.6/1 (blue) and 0/1/1 (green) after LFP at 266 nm. B. 
LFP-determined against known real values, together with the linear fit of the 
experimental points. 
 
Although FBPMe should in principle have a small affinity to 
SAs, its poor hydrophilicity could favor inclusion within the 
proteins. Preference for site I can be attributed to the type of 
predominating interactions (hydrophobic and van der Waals). 
Chiral discrimination in the triplet lifetimes of the drug-SA 
complexes is the only requirement for the successful application of 
this LFP-based methodology, which may not be fulfilled in a 
number of systems. For example, the triplet lifetimes of the parent 
drug FBP in the presence of HSA (τIS = 11.2 µs, τIIS = 35.9 µs, τIR = 
10.2 µs and τIIR= 39 µs)[15b] or PSA (τIS = 6.5 µs, τIIS = 44.5 µs, τIR 
= 6.8 µs and τIIR= 45.0 µs) are too close, and hence the obtained 
values for the percentages of the two enantiomers are not reliable. 
Even in such a case, the problem can be circumvented by choosing a 
protein where the triplet lifetimes of the two enantiomers are 
different enough. For FBP, bovine serum albumin (BSA) provides 
an appropriate chiral selector. Within this protein, a clear 
stereodifferentiation is indeed observed for (S)- and (R)-FBP within 
the binding sites (τIS = 10.8 µs, τIIS = 86.5 µs, τIR = 6.6 µs and τIIR= 
58.6 µs)[15b] As a matter of fact, when the decay traces obtained in 
the presence of BSA for different (S)-FBP/(R)-FBP ratios were 
processed in the usual way, good correlations were found between 
the LFP determined and the real enantiomeric compositions (see 
Figure S7 in the Supporting Information). 
Stereodifferentiation in the triplet excited state interactions 
between chiral analytes and proteins should in principle be a 
common phenomenon; a further example (naproxen/HSA) is shown 
in the Supporting Information (Figure S8). Furthermore, the 
tolerance of this approach to the presence of impurities was nicely 
demonstrated by using commercial Froben® tablets, where the 
content of active principle (racemic FBP) is about 25%; the results 
are shown in Figures S9-S11. For comparison, the application of 
polarimetry, NMR and HPLC-based analysis to the case of FBP is 
given in the Supporting Information (Table 3 and Figures S12 and 
S13). 
In conclusion, a novel method for the straightforward 
determination of enantiomeric compositions is presented here. It is 
based on transient spectroscopy, exploiting the differences in triplet 
lifetimes within serum albumins for chiral recognition. The method 
is fast and simple, as it requires just one measurement per sample to 
provide accurate results. It is highly sensitive and is appropriate for 
analysis of minute (µg) amounts. As further advantages, it avoids 
substrate derivatization as well as chromatographic separation and 
does not depend on the specific rotation on the target compound. All 
together, the above reasons make this LFP-based approach a very 
complementary tool to the existing techniques. 
 
− τ − τ − τ − τ∆ = ∆ + + + +
S S R R
I II I II( t / ) ( t / ) ( t / ) ( t / )S S R R


















































































































































Experimental details for a typical determination of the enantiomeric composition of a 
given sample, i. e. the (S)-FBPMe/(R)-FBPMe/HSA 0.5/0.5/1 ratio follows. 
To prepare the solution containing a mixture of (S)- and (R)-FBPMe and HSA in 
0.5:0.5:1 molar ratio we proceeded as follows: to 10 mL of a 1.25·10-5 M solution of 
(S)-FBPMe, 10 mL of 1.25·10-5 M of (R)-FBPMe in PBS and 2.48 µL of HSA 2·10-3 M 
in PBS were added. The resulting solution (4 mL) was placed in a quartz cuvette and 
submitted to LFP (10 shots for monitoring at 360 nm). The laser flash photolysis 
experiment was performed by using a Q-switched Nd:YAG laser (Quantel Brilliant, 266 
nm, 10 mJ per pulse, 5 ns fwhm) coupled to a mLFP-111 Luzchem miniaturized 
equipment. The absorbance of FBPMe was found to be ca. 0.2 at the laser wavelength, 
corresponding to a concentration of 2.5·10-5 M. The experiment was carried out in PBS 
(pH = 7.4, 0.01 M) at room temperature (22 ºC) and under air atmosphere.  
Under the employed experimental conditions, upon 266 nm excitation, FBPMe absorbs 
ca 17% of the incident ligth (see Figure S14 in the Supporting Information). However, 
this is enough to produce a good quality signal in LFP. Fortunately, control experiments 
show that direct absorption by the protein does not lead to any interfering transient 
absorption. 
Emission of the FBPMe/HSA complex perfectly matched with the calculation for the 
independent emission of the two components, taking into account the relative 
absorbance. This allows to rule out singlet-singlet energy transfer between FBPMe and 














Figure 3. Laser flash photolysis (λexc = 266 nm) of (S)-FBPMe/(R)-FBPMe/HSA at 
molar ratio 0.5:0.5:1. The black trace is the decay obtained at 360 nm, while the red one 
corresponds to the exponential fitting (eq. 1) of the decay. The procedure followed for 
experimental determination of the enantiomeric composition is explained in the text. 
 
To obtain an accurate decay trace, this experiment was repeated at least three times with 
fresh sample; triplet lifetimes and fittings of the decay traces were coincident within the 
experimental error margins (Figure 3).  
The decay trace was fitted with Eq 1. Taking into account that τIS = 31.5 µs, τIIS = 4.1 µs, 
τIR = 157.6 µs, τIIR = 16.6 µs, and that the relationship between the coefficients 
(previously obtained at 1:1 drug/SA molar ratio) is AIS/AIIS = 70/30 and AIR/AIIR = 
68/32, application of Eq 1 leads to: AIS = 0.00628 ± 0.00017,AIIS = 0.00269 ± 0.00017, 
AIR = 0.00608 ± 0.00014, AIIR = 0.00286 ± 0.00014. 




Operating in this way, the percentage of (S)-FBPMe was found to be 50%. 
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